Univariate and multivariable analyses of risk factors for H. pylori eradication failure
| Characteristics | N | Univariate analysis | Multivariable analysis | ||
| OR (95% CI) | P value | OR (95% CI) | P value | ||
| Age | |||||
| ≤ 30 | 5400 | 1.00 | – | 1.00 | – |
| 30–40 | 5634 | 1.25 (1.12 to 1.41) | <0.001 | 1.25 (1.11 to 1.41) | <0.001 |
| 40–50 | 3774 | 1.43 (1.26 to 1.62) | <0.001 | 1.43 (1.26 to 1.62) | <0.001 |
| 50–60 | 4310 | 1.68 (1.49 to 1.89) | <0.001 | 1.70 (1.51 to 1.91) | <0.001 |
| > 60 | 2586 | 2.04 (1.79 to 2.32) | < 0.001 | 2.01 (1.76 to 2.29) | < 0.001 |
| Sex | |||||
| Male | 10 257 | 1.00 | – | ||
| Female | 11 447 | 0.98 (0.91 to 1.06) | 0.646 | ||
| Date of treatment | |||||
| 2017 | 3695 | 1.00 | – | 1.00 | – |
| 2018 | 6123 | 0.82 (0.73 to 0.91) | <0.001 | 0.85 (0.75 to 0.95) | 0.005 |
| 2019 | 6740 | 0.86 (0.77 to 0.96) | 0.007 | 0.90 (0.80 to 1.01) | 0.071 |
| 2020 | 5146 | 0.80 (0.71 to 0.90) | <0.001 | 0.86 (0.76 to 0.97) | 0.017 |
| Season | |||||
| Spring | 4008 | 1.00 | – | ||
| Summer | 5489 | 0.86 (0.77 to 0.96) | 0.009 | ||
| Autumn | 5828 | 0.88 (0.78 to 0.98) | 0.021 | ||
| Winter | 6379 | 0.88 (0.79 to 0.98) | 0.024 | ||
| Antibiotic regimens | |||||
| Amoxicillin+furazolidone | 16 230 | 1.00 | – | 1.00 | – |
| Amoxicillin+clarithromycin | 3885 | 1.19 (1.08 to 1.32) | 0.001 | 1.21 (1.09 to 1.34) | <0.001 |
| Furazolidone+clarithromycin | 1589 | 2.99 (2.66 to 3.36) | <0.001 | 2.97 (2.64 to 3.34) | <0.001 |
| Duration | |||||
| 10 | 5348 | 1.00 | – | 1.00 | – |
| 14 | 16 356 | 0.81 (0.75 to 0.89) | <0.001 | 0.89 (0.82 to 0.97) | 0.011 |
| Proton pump inhibitor | |||||
| Rabeprazole10mg | 8826 | 1.00 | – | ||
| Rabeprazole20mg | 21 | 1.05 (0.31 to 3.55) | 0.944 | ||
| Pantoprazole | 5455 | 1.11 (1.01 to 1.22) | 0.029 | ||
| Esomeprazole | 4530 | 1.11 (1.00 to 1.23) | 0.049 | ||
| Omeprazole | 2010 | 0.83 (0.72 to 0.96) | 0.014 | ||
| Lansoprazole | 862 | 1.02 (0.84 to 1.25) | 0.818 | ||